{
    "clinical_study": {
        "@rank": "72264", 
        "acronym": "GT-COG", 
        "arm_group": [
            {
                "arm_group_label": "Experimental", 
                "arm_group_type": "Experimental", 
                "description": "Patient's with Diabetic Ketoacidosis receiving standard of care treatment with insulin drip, IV fluids and close monitoring, with the addition of subcutaneous Insulin Glargine within 2 hours of diagnosis."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Active Comparator", 
                "description": "Patient's with Diabetic Ketoacidosis receiving standard of care treatment with insulin drip, IV fluids and close monitoring."
            }
        ], 
        "brief_summary": {
            "textblock": "To determine if co-administration of subcutaneous (SQ)Insulin glargine in combination with\n      intravenous (IV) insulin decreases the time to resolution of ketoacidosis and requirement\n      for ICU admission compared to IV insulin with delayed administration of SQ glargine for the\n      treatment of DKA."
        }, 
        "brief_title": "Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetic Ketoacidosis", 
        "condition_browse": {
            "mesh_term": [
                "Acidosis", 
                "Diabetic Ketoacidosis", 
                "Emergencies", 
                "Ketosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >18 years\n\n          -  Blood Glucose >200\n\n          -  pH < 7.3\n\n          -  Bicarbonate < 18\n\n          -  Ketonemia or Ketonuria\n\n          -  Anion Gap > or = 16\n\n        Exclusion Criteria:\n\n          -  Age < 18 years\n\n          -  Pregnant\n\n          -  ESRD\n\n          -  Prisoners\n\n          -  Patients in shock or requiring emergency surgery\n\n          -  Those unwilling to consent for the trial\n\n          -  Allergic to Insulin Glargine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02006342", 
            "org_study_id": "HSC-MS-12-0535"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental", 
                "intervention_name": "Insulin Glargine", 
                "intervention_type": "Drug", 
                "other_name": "Lantus Insulin"
            }, 
            {
                "arm_group_label": [
                    "Experimental", 
                    "Control"
                ], 
                "intervention_name": "Regular Insulin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes Mellitus", 
            "Diabetic Ketoacidosis", 
            "Insulin Glargine", 
            "Anion gap", 
            "Metabolic acidosis"
        ], 
        "lastchanged_date": "December 4, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Memorial Herman Hospital-Texas Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77026"
                    }, 
                    "name": "Lyndon B Johnson Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis: A Pilot Study", 
        "overall_official": {
            "affiliation": "The University of Texas Health Science Center, Houston", 
            "last_name": "Pratik B Doshi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Anion Gap is a measure of acidosis that results from decompensated Diabetes Mellitus. Acidosis is the result of the body being unable to utilize glucose for energy production and instead uses fatty acid metabolism resulting in ketone formation. Anion Gap is a surrogate measure for the level of ketones resulting in the excess acid production.", 
            "measure": "Time to anion gap closure", 
            "safety_issue": "No", 
            "time_frame": "Monitored from hospital admission to discharge"
        }, 
        "reference": {
            "PMID": "17508198", 
            "citation": "Shankar V, Haque A, Churchwell KB, Russell W. Insulin glargine supplementation during early management phase of diabetic ketoacidosis in children. Intensive Care Med. 2007 Jul;33(7):1173-8. Epub 2007 May 17."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02006342"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of Texas Health Science Center, Houston", 
            "investigator_full_name": "Pratik B Doshi", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The goal was to determine if we could reduce the amount of patients admitted to the ICU by providing more efficient resolution of the critical condition which is the acidosis.", 
                "measure": "Rate of ICU admission", 
                "safety_issue": "No", 
                "time_frame": "Participants will followed for the duration of the Emergency Department stay, an expected average of 12 hours"
            }, 
            {
                "description": "Determine the amount of time patient is admitted to the intensive care unit with the goal of assessing if more efficient correction of the acidosis results in decreased time in the intensive care unit for the patients.", 
                "measure": "Intensive care unit Length of Stay", 
                "safety_issue": "No", 
                "time_frame": "Participants will followed for the duration of the hospital stay, an expected average of 7 days"
            }, 
            {
                "description": "Hospital length of stay was determined to assess whether a more efficient correction of the acidosis will result in decreased time that the patient is admitted to the hospital.", 
                "measure": "Hospital Length of stay", 
                "safety_issue": "No", 
                "time_frame": "Participants will followed for the duration of the hospital stay, an expected average of 7 days"
            }, 
            {
                "description": "To determine whether it is safe to administer both IV and subcutaneous insulin, it is important to assure that patient's glucose does not drop to critically low level and lead to adverse events.", 
                "measure": "Rate of hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will followed for the duration of the hospital stay, an expected average of 7 days"
            }
        ], 
        "source": "The University of Texas Health Science Center, Houston", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The University of Texas Health Science Center, Houston", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}